Qian Jun, Feng Gan-Sheng, Vogl Thomas
Department of Radiology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China.
World J Gastroenterol. 2003 Sep;9(9):1885-91. doi: 10.3748/wjg.v9.i9.1885.
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world, responsible for an estimated one million deaths annually. It has a poor prognosis due to its rapid infiltrating growth and complicating liver cirrhosis. Surgical resection, liver transplantation and cryosurgery are considered the best curative options, achieving a high rate of complete response, especially in patients with small HCC and good residual liver function. In nonsurgery, regional interventional therapies have led to a major breakthrough in the management of unresectable HCC, which include transarterial chemoembolization (TACE), percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), microwave coagulation therapy (MCT), laser-induced thermotherapy (LITT), etc. As a result of the technical development of locoregional approaches for HCC during the recent decades, the range of combined interventional therapies has been continuously extended. Most combined multimodal interventional therapies reveal their enormous advantages as compared with any single therapeutic regimen alone, and play more important roles in treating unresectable HCC.
肝细胞癌(HCC)是世界上最常见的恶性肿瘤之一,每年估计导致100万人死亡。由于其浸润性生长迅速且常并发肝硬化,预后较差。手术切除、肝移植和冷冻手术被认为是最佳的治愈选择,能实现较高的完全缓解率,尤其是在小肝癌且残余肝功能良好的患者中。在非手术治疗方面,区域介入治疗在不可切除HCC的管理上取得了重大突破,包括经动脉化疗栓塞术(TACE)、经皮乙醇注射(PEI)、射频消融(RFA)、微波凝固治疗(MCT)、激光诱导热疗(LITT)等。由于近几十年来HCC局部区域治疗方法的技术发展,联合介入治疗的范围不断扩大。与任何单一治疗方案相比,大多数联合多模式介入治疗都显示出巨大优势,在治疗不可切除HCC中发挥着更重要的作用。